pioglitazone has been researched along with Anasarca in 36 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a randomized, double-blind, placebo-controlled study to examine whether pioglitazone can reduce the risk of type 2 diabetes mellitus in adults with impaired glucose tolerance." | 9.15 | Pioglitazone for diabetes prevention in impaired glucose tolerance. ( Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Hodis, HN; Kitabchi, AE; Mack, WJ; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Stentz, FB; Tripathy, D; Williams, K, 2011) |
| " We examined the effects of exenatide on FGF21 in patients with type 2 diabetes and in a diet-induced mouse model of obesity (DIO)." | 9.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| "To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes." | 8.95 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. ( Chen, TH; Lee, M; Liao, HW; Ovbiagele, B; Saver, JL; Wu, YL, 2017) |
| "Fenofibrate did not inhibit mechanical allodynia or paw edema induced by phorbol-12,13-didecanoate (PDD), a protein kinase C activator, in rats." | 5.34 | Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. ( Bertollo, CM; Coelho, MM; Costa, KA; Nascimento, EB; Oliveira, AC; Rocha, LT, 2007) |
| "Pioglitazone is an insulin-sensitizer with a thiazolidinedione structure." | 5.33 | Relationship between plasma hANP level and pretibial edema by pioglitazone treatment. ( Kahara, T; Kaneko, S; Misaki, T; Sakurai, M; Shimizu, A; Takamura, T; Takeshita, Y, 2005) |
| "We conducted a randomized, double-blind, placebo-controlled study to examine whether pioglitazone can reduce the risk of type 2 diabetes mellitus in adults with impaired glucose tolerance." | 5.15 | Pioglitazone for diabetes prevention in impaired glucose tolerance. ( Banerji, M; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Hodis, HN; Kitabchi, AE; Mack, WJ; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Stentz, FB; Tripathy, D; Williams, K, 2011) |
| " We examined the effects of exenatide on FGF21 in patients with type 2 diabetes and in a diet-induced mouse model of obesity (DIO)." | 5.15 | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. ( Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P, 2011) |
| "Pioglitazone (PIO), a thiazolidinedione (TZD), is reported to be highly effective in the treatment of type 2 diabetes mellitus, but is associated with edema, heart failure, and weight gain." | 5.14 | Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. ( Bailey, AL; Chan, JY; Grossman, LD; Parlan, G; Yee, G; Yu, M, 2009) |
| " Vildagliptin provided additional HbA(1c) lowering to that achieved with metformin alone and comparable to that achieved with pioglitazone, with only pioglitazone causing weight gain." | 5.14 | Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. ( Bolli, G; Colin, L; Dotta, F; Goodman, M; Minic, B, 2009) |
| " The effect of pioglitazone on composite endpoints was evaluated, including all-cause death, myocardial infarction (MI), and stroke, as well as safety events of edema and serious heart failure, in subgroups using nitrates, RAS blockers, or insulin at baseline." | 5.14 | Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). ( Charbonnel, B; Erdmann, E; Spanheimer, R, 2010) |
| "A phase II trial was initiated to analyze the activity of continuously administered pioglitazone and rofecoxib combined with low-dose chemotherapy (capecitabine or temozolomide) in patients with high-grade gliomas (glioblastoma or anaplastic glioma)." | 5.12 | Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study. ( Baumgart, U; Bogdahn, U; Hau, P; Hirschmann, B; Kunz-Schughart, L; Muhleisen, H; Reichle, A; Ruemmele, P; Steinbrecher, A; Weimann, E, 2007) |
| "To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes." | 4.95 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. ( Chen, TH; Lee, M; Liao, HW; Ovbiagele, B; Saver, JL; Wu, YL, 2017) |
| "Sequence symmetry analyses were undertaken to investigate the risk of peripheral oedema, as measured by incident furosemide dispensing, and risk of hospitalisations for heart failure." | 3.81 | Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries. ( Chan, EW; Choi, NK; Griffiths, J; Kimura, M; Kimura, T; Kubota, K; Lai, EC; Man, KK; Nguyen, TA; Ooba, N; Park, BJ; Pratt, NL; Roughead, EE; Sato, T; Shin, JY; Wang, T; Wong, IC; Yang, YH, 2015) |
| "Pioglitazone was associated with a significant increase in body weight and edema." | 3.75 | Adverse effect of pioglitazone in military personnel and their families: a preliminary report. ( Benjasuratwong, Y; Patarakitvanit, S; Satyapan, N; Temboonkiat, S; Vudhironarit, T, 2009) |
| "Peroxisome proliferator-activated receptor (PPAR)-gamma ligand, pioglitazone (PIO), is reported to induce edema especially in postmenopausal women." | 3.74 | Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats. ( Hasegawa, K; Hayashi, K; Homma, K; Ito, O; Kanda, T; Omata, K; Saruta, T; Sugano, N; Tatematsu, S; Wakino, S; Yoshioka, K, 2008) |
| "Muraglitazar is a dual (alpha/gamma) PPAR activator." | 2.74 | Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. ( Fiedorek, FT; Rubin, CJ; Viraswami-Appanna, K, 2009) |
| "Pioglitazone is a thiazolidinedione that displays high affinity for PPARγ(1) and PPARγ(2), which are predominately expressed in adipose tissue." | 2.46 | Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. ( Derosa, G, 2010) |
| " In these trials, adverse events were recorded, as were details of laboratory blood values, urine analysis, vital signs and electrocardiograms." | 2.41 | Safety profile of pioglitazone. ( Belcher, G; Hanefeld, M, 2001) |
| "The first thiazolidinedione derivative drug for diabetes, troglitazone, was found to cause fatal hepatotoxicity, although it was judged as safe during the clinical trial." | 2.41 | [Evaluation of thiazolidinedione derivative drugs for safety]. ( Iwata, M; Kobayashi, M, 2001) |
| "The frequency of edema and cardiac failure was significantly higher with TZDs than in other patients (18% and 7." | 1.37 | Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database. ( Berthet, S; Lapeyre-Mestre, M; Montastruc, JL; Olivier, P, 2011) |
| "Fenofibrate did not inhibit mechanical allodynia or paw edema induced by phorbol-12,13-didecanoate (PDD), a protein kinase C activator, in rats." | 1.34 | Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma. ( Bertollo, CM; Coelho, MM; Costa, KA; Nascimento, EB; Oliveira, AC; Rocha, LT, 2007) |
| "Pioglitazone is an insulin-sensitizer with a thiazolidinedione structure." | 1.33 | Relationship between plasma hANP level and pretibial edema by pioglitazone treatment. ( Kahara, T; Kaneko, S; Misaki, T; Sakurai, M; Shimizu, A; Takamura, T; Takeshita, Y, 2005) |
| "Rosiglitazone was associated with a 0." | 1.32 | Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. ( Colman, PG; Hussein, Z; Nankervis, AJ; Proietto, J; Wentworth, JM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (61.11) | 29.6817 |
| 2010's | 13 (36.11) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Xue, J | 1 |
| Liu, W | 1 |
| Shi, F | 1 |
| Zheng, J | 1 |
| Ma, J | 1 |
| Colca, JR | 1 |
| VanderLugt, JT | 1 |
| Adams, WJ | 1 |
| Shashlo, A | 1 |
| McDonald, WG | 1 |
| Liang, J | 1 |
| Zhou, R | 1 |
| Orloff, DG | 1 |
| Yamamoto, A | 1 |
| Kakuta, H | 1 |
| Sugimoto, Y | 1 |
| Mesinkovska, NA | 1 |
| Tellez, A | 1 |
| Dawes, D | 1 |
| Piliang, M | 1 |
| Bergfeld, W | 1 |
| Roughead, EE | 1 |
| Chan, EW | 1 |
| Choi, NK | 1 |
| Kimura, M | 1 |
| Kimura, T | 1 |
| Kubota, K | 1 |
| Lai, EC | 1 |
| Man, KK | 1 |
| Nguyen, TA | 1 |
| Ooba, N | 1 |
| Park, BJ | 1 |
| Sato, T | 1 |
| Shin, JY | 1 |
| Wang, T | 1 |
| Griffiths, J | 1 |
| Wong, IC | 1 |
| Yang, YH | 1 |
| Pratt, NL | 1 |
| Houshmand, G | 1 |
| Mansouri, MT | 1 |
| Naghizadeh, B | 1 |
| Hemmati, AA | 1 |
| Hashemitabar, M | 1 |
| Liao, HW | 1 |
| Saver, JL | 1 |
| Wu, YL | 1 |
| Chen, TH | 1 |
| Lee, M | 1 |
| Ovbiagele, B | 1 |
| Stafylas, PC | 1 |
| Sarafidis, PA | 1 |
| Lasaridis, AN | 1 |
| Ruaño, G | 1 |
| Bernene, J | 1 |
| Windemuth, A | 1 |
| Bower, B | 1 |
| Wencker, D | 1 |
| Seip, RL | 1 |
| Kocherla, M | 1 |
| Holford, TR | 1 |
| Petit, WA | 1 |
| Hanks, S | 1 |
| Grossman, LD | 1 |
| Parlan, G | 1 |
| Bailey, AL | 1 |
| Yee, G | 1 |
| Yu, M | 1 |
| Chan, JY | 1 |
| Dorkhan, M | 1 |
| Dencker, M | 1 |
| Stagmo, M | 1 |
| Groop, L | 1 |
| Rahimian, R | 1 |
| Fakhfouri, G | 1 |
| Rasouli, MR | 1 |
| Nouri, M | 1 |
| Nezami, BG | 1 |
| Paydar, MJ | 1 |
| Asadi-Amoli, F | 1 |
| Dehpour, AR | 1 |
| Mikhail, N | 1 |
| Bolli, G | 1 |
| Dotta, F | 1 |
| Colin, L | 1 |
| Minic, B | 1 |
| Goodman, M | 1 |
| Rubin, CJ | 1 |
| Viraswami-Appanna, K | 1 |
| Fiedorek, FT | 1 |
| Derosa, G | 1 |
| Erdmann, E | 1 |
| Spanheimer, R | 1 |
| Charbonnel, B | 1 |
| Vudhironarit, T | 1 |
| Benjasuratwong, Y | 1 |
| Patarakitvanit, S | 1 |
| Temboonkiat, S | 1 |
| Satyapan, N | 1 |
| DeFronzo, RA | 1 |
| Tripathy, D | 1 |
| Schwenke, DC | 1 |
| Banerji, M | 1 |
| Bray, GA | 1 |
| Buchanan, TA | 1 |
| Clement, SC | 1 |
| Henry, RR | 1 |
| Hodis, HN | 1 |
| Kitabchi, AE | 1 |
| Mack, WJ | 1 |
| Mudaliar, S | 1 |
| Ratner, RE | 1 |
| Williams, K | 1 |
| Stentz, FB | 1 |
| Musi, N | 1 |
| Reaven, PD | 1 |
| Berthet, S | 1 |
| Olivier, P | 1 |
| Montastruc, JL | 1 |
| Lapeyre-Mestre, M | 1 |
| Samson, SL | 1 |
| Sathyanarayana, P | 1 |
| Jogi, M | 1 |
| Gonzalez, EV | 1 |
| Gutierrez, A | 1 |
| Krishnamurthy, R | 1 |
| Muthupillai, R | 1 |
| Chan, L | 1 |
| Bajaj, M | 1 |
| Blankfield, RP | 1 |
| Kawamori, R | 2 |
| Kobayashi, M | 2 |
| Iwata, M | 2 |
| Hiratani, K | 1 |
| Buse, JB | 1 |
| Hussein, Z | 1 |
| Wentworth, JM | 1 |
| Nankervis, AJ | 1 |
| Proietto, J | 1 |
| Colman, PG | 1 |
| Kahara, T | 1 |
| Takamura, T | 1 |
| Misaki, T | 1 |
| Sakurai, M | 1 |
| Takeshita, Y | 1 |
| Shimizu, A | 1 |
| Kaneko, S | 1 |
| Majima, T | 1 |
| Komatsu, Y | 1 |
| Doi, K | 1 |
| Shigemoto, M | 1 |
| Takagi, C | 1 |
| Fukao, A | 1 |
| Corners, J | 1 |
| Nakao, K | 1 |
| Berlie, HD | 1 |
| Kalus, JS | 1 |
| Jaber, LA | 1 |
| Oliveira, AC | 1 |
| Bertollo, CM | 1 |
| Rocha, LT | 1 |
| Nascimento, EB | 1 |
| Costa, KA | 1 |
| Coelho, MM | 1 |
| Kanazawa, A | 1 |
| Yoshioka, K | 1 |
| Wakino, S | 1 |
| Homma, K | 1 |
| Kanda, T | 1 |
| Tatematsu, S | 1 |
| Hasegawa, K | 1 |
| Sugano, N | 1 |
| Ito, O | 1 |
| Omata, K | 1 |
| Saruta, T | 1 |
| Hayashi, K | 1 |
| Hau, P | 1 |
| Kunz-Schughart, L | 1 |
| Bogdahn, U | 1 |
| Baumgart, U | 1 |
| Hirschmann, B | 1 |
| Weimann, E | 1 |
| Muhleisen, H | 1 |
| Ruemmele, P | 1 |
| Steinbrecher, A | 1 |
| Reichle, A | 1 |
| King, AB | 1 |
| Hanefeld, M | 1 |
| Belcher, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects With Type 2 Diabetes[NCT00240383] | Phase 2/Phase 3 | 1,260 participants | Interventional | 2002-05-31 | Completed | ||
| PROspective PioglitAzone Clinical Trial In MacroVascular Events: A Macrovascular Outcome Study in Type 2 Diabetic Patients Comparing Pioglitazone With Placebo in Addition to Existing Therapy[NCT00174993] | Phase 3 | 4,373 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| Actos Now for Prevention of Diabetes (ACT NOW)[NCT00220961] | Phase 3 | 602 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Prospective, Randomized, Parallel-group, Adaptive Design Phase IIb/III, Multicenter Study, to Assess the Efficacy of Polychemotherapy for Inducing Remission of Newly Diagnosed Type 2 Diabetes.[NCT04271189] | Phase 2/Phase 3 | 180 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes[NCT01741467] | 110 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus[NCT01432405] | Phase 4 | 24 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fasting Plasma Glucose (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | mg/dl (Mean) |
|---|---|
| Placebo | -4.0 |
| Pioglitazone | -10.7 |
Insulin sensitivity The Matsuda index was calculated as 10,000/square root of (pre-meal glucose x pre-meal insulin x mean 120 min post-meal glucose x mean 120 min post-meal insulin), with higher numbers indicating better the insulin sensitivity. (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | matsuda index (Mean) |
|---|---|
| Placebo | 0.7 |
| Pioglitazone | 3.6 |
Insulin secretion (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | nmol (Mean) |
|---|---|
| Placebo | 35 |
| Pioglitazone | 25 |
carotid intima thickness (NCT00220961)
Timeframe: Baseline versus 2.4 years
| Intervention | percentage of intima (Mean) |
|---|---|
| Placebo | 1.7 |
| Pioglitazone | 3.2 |
Percentage of Participants with Type 2 Diabetes at 2.4 years Post-randomization (NCT00220961)
Timeframe: 2.4 years
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 16.1 |
| Pioglitazone | 5.0 |
The effect of exenatide and pioglitazone on liver fat content after one year of treatment in patients with type 2 diabetes. (NCT01432405)
Timeframe: one year
| Intervention | percent of liver fat (Mean) |
|---|---|
| Pioglitazone and Exenatide | 4.7 |
| Pioglitazone | 6.5 |
the effect of the intervention on plasma adiponectin levels. (NCT01432405)
Timeframe: one year
| Intervention | microgram per ml (Mean) |
|---|---|
| Pioglitazone and Exenatide | 23.2 |
| Pioglitazone | 15.8 |
9 reviews available for pioglitazone and Anasarca
| Article | Year |
|---|---|
Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Edema; Fractures, Bone; Humans; Hypoglycemic Age | 2017 |
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
Topics: Animals; Cardiovascular Diseases; Cardiovascular System; Edema; Heart Failure; Humans; Pioglitazone; | 2009 |
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipepti | 2008 |
Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
Topics: Administration, Oral; Blood Glucose; Cardiovascular System; Diabetes Mellitus, Type 2; Edema; Fractu | 2010 |
[Pioglitazone].
Topics: Animals; Chemical and Drug Induced Liver Injury; Diabetes Mellitus, Type 2; Edema; Humans; Hypoglyce | 2002 |
Thiazolidinediones and the risk of edema: a meta-analysis.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Edema; Humans; Piogl | 2007 |
[Adverse effects of insulin sensitisers and biguanides].
Topics: Acidosis, Lactic; Animals; Biguanides; Capillary Permeability; Chemical and Drug Induced Liver Injur | 2007 |
Safety profile of pioglitazone.
Topics: Cardiovascular System; Edema; Humans; Hypoglycemic Agents; Pioglitazone; Randomized Controlled Trial | 2001 |
[Evaluation of thiazolidinedione derivative drugs for safety].
Topics: Animals; Chemical and Drug Induced Liver Injury; Chromans; Clinical Trials as Topic; Edema; Heart Fa | 2001 |
11 trials available for pioglitazone and Anasarca
| Article | Year |
|---|---|
Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.
Topics: Adiponectin; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Edema; Fema | 2013 |
Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Canada; Diabetes Mellitus, Type 2; Edema; Female; Fol | 2009 |
Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes.
Topics: Aged; Atrial Function, Left; Diabetes Mellitus, Type 2; Edema; Electrocardiography; Female; Humans; | 2009 |
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptid | 2009 |
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; D | 2009 |
Pioglitazone and the risk of cardiovascular events in patients with Type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20).
Topics: Age of Onset; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic An | 2010 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Pioglitazone for diabetes prevention in impaired glucose tolerance.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Ed | 2011 |
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, | 2011 |
Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus.
Topics: Administration, Oral; Aged; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholestero | 2006 |
Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Capecitabin | 2007 |
A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones.
Topics: Body Weight; Cholesterol, LDL; Chromans; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemoglob | 2000 |
16 other studies available for pioglitazone and Anasarca
| Article | Year |
|---|---|
Pleural Effusion Due to Use of Pioglitazone: A Case Report.
Topics: Aged; Diabetes Mellitus, Type 2; Diuretics; Edema; Female; Humans; Hypoglycemic Agents; Pioglitazone | 2020 |
Involvement of glucocorticoid receptor activation on anti-inflammatory effect induced by peroxisome proliferator-activated receptor γ agonist in mice.
Topics: Anilides; Animals; Carrageenan; Dexamethasone; Edema; Female; Mice; Mice, Inbred ICR; Mifepristone; | 2014 |
The use of oral pioglitazone in the treatment of lichen planopilaris.
Topics: Administration, Oral; Alopecia; Disease Progression; Edema; Female; Follow-Up Studies; Humans; Liche | 2015 |
Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries.
Topics: Databases, Factual; Edema; Ethnicity; Furosemide; Heart Failure; Hospitalization; Humans; Pioglitazo | 2015 |
Potentiation of indomethacin-induced anti-inflammatory response by pioglitazone in carrageenan-induced acute inflammation in rats: Role of PPARγ receptors.
Topics: Animals; Anti-Inflammatory Agents; Carrageenan; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synerg | 2016 |
Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Drug-Related Side Effects | 2009 |
Effect of pioglitazone on sciatic nerve ischemia/reperfusion injury in rats.
Topics: Animals; Behavior, Animal; Edema; Male; Pioglitazone; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2009 |
Adverse effect of pioglitazone in military personnel and their families: a preliminary report.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Edema; Family; Female; Humans; Hypoglycemic Agents; Incidenc | 2009 |
Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Databases, Factual; Diabetes Mellitus, Type 2; | 2011 |
Blood pressure, fluid retention and the cardiovascular risk of drugs.
Topics: Antipsychotic Agents; Atherosclerosis; Blood Pressure; Cardiovascular System; Cyclooxygenase 2 Inhib | 2012 |
[Biguanide, pioglitazone and alpha-glucosidase inhibitors].
Topics: Acidosis, Lactic; Biguanides; Body Weight; Chemical and Drug Induced Liver Injury; Digestive System; | 2012 |
Glitazones and heart failure: critical appraisal for the clinician.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diuretics; Edema; Heart Failure; | 2003 |
Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Diabetes Mellitus, Type 2; Edema; Female; Glycated Hemo | 2004 |
Relationship between plasma hANP level and pretibial edema by pioglitazone treatment.
Topics: Aged; Aged, 80 and over; Atrial Natriuretic Factor; Diabetes Mellitus, Type 2; Edema; Female; Humans | 2005 |
Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Carrageenan; Disease Models, Animal; Dose-Response Re | 2007 |
Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats.
Topics: Animals; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Dinoprostone; Disease Models, Anima | 2008 |